Latest Ratios: P/E Ratio 115.3x · EV/EBITDA 8.3x · ROE -2.2%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $94M | $451M | $102M | $146M | $124M | $215M | $121M | $90M | $39M | $32M | $17M |
| Enterprise Value | $741M | $442M | $749M | $768M | $825M | $788M | $723M | $482M | $350M | $231M | $63M |
| P/E Ratio → | 115.29 | — | 124.52 | 9.65 | 46.47 | — | — | — | 2.91 | — | — |
| P/S Ratio | 0.68 | 3.05 | 0.74 | 1.03 | 0.90 | 1.86 | 1.29 | 1.27 | 0.73 | 1.06 | 2.05 |
| P/B Ratio | 0.17 | 0.85 | 0.18 | 0.24 | 0.19 | 0.34 | 0.26 | 0.19 | 0.13 | 0.12 | 0.08 |
| P/FCF | — | 6.13 | — | 2.49 | — | — | — | — | — | — | — |
| P/OCF | 1.35 | 6.13 | 1.45 | 2.13 | 1.62 | 3.12 | 3.50 | 2.46 | 1.57 | 2.77 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.98 | 5.41 | 5.45 | 6.01 | 6.80 | 7.73 | 6.81 | 6.59 | 7.63 | 7.85 |
| EV / EBITDA | 8.35 | 5.69 | 8.43 | 7.93 | 8.56 | 9.35 | 13.64 | 6.54 | 6.54 | 7.60 | 7.73 |
| EV / EBIT | 22.68 | 22.52 | 21.16 | 14.60 | 18.24 | 20.71 | 44.68 | 17.81 | 11.86 | 31.37 | — |
| EV / FCF | — | 6.01 | — | 13.16 | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 78.9% | 80.1% | 81.6% | 86.6% | 88.4% | 90.8% | 93.0% | 93.8% | 82.3% |
| Operating Margin | — | — | 23.6% | 26.9% | 28.2% | 31.9% | — | 70.6% | 41.8% | 24.3% | -27.4% |
| Net Profit Margin | -8.2% | -8.2% | 4.8% | 14.6% | 14.0% | 15.2% | -2.1% | 13.1% | 25.4% | -0.1% | -78.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -2.2% | -2.2% | 1.1% | 3.3% | 3.0% | 3.2% | -0.4% | 2.4% | 4.8% | -0.0% | -6.4% |
| ROA | -1.0% | -1.0% | 0.5% | 1.5% | 1.4% | 1.5% | -0.2% | 1.2% | 2.4% | -0.0% | -4.3% |
| ROIC | — | — | 2.0% | 2.2% | 2.3% | 2.4% | — | 5.1% | 3.1% | 1.6% | -1.1% |
| ROCE | — | — | 5.3% | 5.5% | 5.4% | 4.1% | — | 8.3% | 6.9% | 3.0% | -1.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 1.18 | 1.03 | 1.09 | 0.91 | 1.33 | 0.86 | 1.05 | 0.79 | 0.33 |
| Debt / EBITDA | — | — | 7.36 | 6.44 | 7.31 | 6.88 | 11.46 | 5.36 | 5.88 | 6.70 | 8.10 |
| Net Debt / Equity | — | -0.02 | 1.16 | 1.03 | 1.08 | 0.90 | 1.32 | 0.85 | 1.04 | 0.77 | 0.23 |
| Net Debt / EBITDA | -0.12 | -0.12 | 7.29 | 6.43 | 7.27 | 6.79 | 11.36 | 5.32 | 5.81 | 6.54 | 5.71 |
| Debt / FCF | — | -0.12 | — | 10.67 | — | — | — | — | — | — | — |
| Interest Coverage | 0.62 | 0.62 | 1.23 | 1.70 | 1.79 | 1.93 | 0.87 | 1.55 | 1.97 | 0.99 | -0.53 |
Net cash position: cash ($9M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | — | — | 0.03 | 0.02 | 0.05 | 0.05 | 1.11 | 1.30 | 0.03 | 0.05 | 0.68 |
| Quick Ratio | — | — | 0.03 | 0.02 | 0.05 | 0.05 | 1.11 | 1.30 | 0.03 | 2.75 | 0.65 |
| Cash Ratio | — | — | 0.01 | 0.00 | 0.01 | 0.01 | 0.15 | 0.11 | 0.01 | 0.03 | 0.61 |
| Asset Turnover | — | 0.12 | 0.11 | 0.11 | 0.10 | 0.09 | 0.08 | 0.08 | 0.08 | 0.06 | 0.04 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | 1.52 |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 63.5% | 11.6% | 58.8% | 40.6% | 47.1% | 24.4% | 33.1% | 32.6% | 48.5% | 47.3% | 23.4% |
| Payout Ratio | — | — | 902.6% | 286.4% | 305.2% | 297.9% | — | 315.9% | 140.6% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.9% | — | 0.8% | 10.4% | 2.2% | — | — | — | 34.3% | — | — |
| FCF Yield | — | 16.3% | — | 40.1% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 1.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.7% | 0.0% | 0.0% |
| Total Shareholder Yield | 63.5% | 12.9% | 58.8% | 40.6% | 47.1% | 24.4% | 33.1% | 32.6% | 49.2% | 47.3% | 23.4% |
| Shares Outstanding | — | $13M | $3M | $3M | $3M | $2M | $2M | $1M | $878840 | $784680 | $372080 |
Includes 30+ ratios · 14 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GMRE stock.
Global Medical REIT Inc.'s current P/E ratio is 115.3x. The historical average is 45.9x. This places it at the 75th percentile of its historical range.
Global Medical REIT Inc.'s current EV/EBITDA is 8.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 8.2x.
Global Medical REIT Inc.'s return on equity (ROE) is -2.2%. The historical average is -20.6%.
Based on historical data, Global Medical REIT Inc. is trading at a P/E of 115.3x. This is at the 75th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Global Medical REIT Inc.'s current dividend yield is 63.51%.
Key Metrics
Top Statement Risk
Unsustainable dividend and leverage
Valuation Disconnects Amidst Earnings Volatility
As reported in recent financial statements, GMRE's P/FFO multiple has fluctuated wildly, reaching 39.64 in 2025Q4, which suggests that traditional valuation metrics are currently distorted by the company's inconsistent earnings profile and the market's uncertainty regarding future cash flow generation.
The extreme variance in P/FFO multiples over the last ten quarters indicates that the market is struggling to price the REIT's earnings power, likely due to the instability of FFO per share. Investors should monitor whether the current valuation reflects a genuine discount to private market cap rates or if it is merely a reaction to the persistent negative AFFO trends.
NOI Margin Volatility Masks Operational Challenges
Based on reported quarterly figures, the NOI margin exhibited extreme instability, swinging from 42.7% in 2025Q3 to 100% in 2025Q4, which suggests that the company's property-level profitability is not as predictable as the standard triple-net lease model would typically imply.
This erratic margin performance warrants further investigation into whether these fluctuations are driven by non-recurring accounting adjustments or underlying operational inefficiencies. The lack of consistent margin expansion suggests that the REIT's growth strategy has yet to achieve the necessary scale to offset its fixed cost structure.
Dividend Sustainability Remains Highly Questionable
According to the company's quarterly financial disclosures, the FFO payout ratio reached 4.1% in 2025Q4, yet this figure appears misleading when contrasted with the negative AFFO per share, indicating that the dividend is not supported by recurring cash flow.
The disconnect between the FFO payout ratio and the actual cash-generating capacity of the portfolio suggests that the current dividend policy may be unsustainable. Investors should be wary of the reliance on external capital to fund distributions, as this practice often precedes a dividend reduction in REITs with strained liquidity.
Debt Burden Constrains Financial Flexibility
As reported in recent financial filings, the debt-to-equity ratio climbed to 1.44 by 2025Q3, signaling that the REIT's reliance on external financing has intensified even as the broader interest rate environment has become increasingly punitive for small-cap healthcare operators.
The rising debt load, combined with an interest coverage ratio that dipped to 0.12 in 2025Q4, suggests that the company's ability to service its obligations is under significant pressure. This leverage profile warrants close monitoring, as it limits the REIT's capacity to pursue accretive acquisitions or navigate potential sector-specific downturns.
Misapplication of P/E to REITs
The market's reliance on the P/E ratio for GMRE is fundamentally flawed, as reported in financial statements, because it fails to account for the significant non-cash depreciation charges that artificially depress net income and obscure the REIT's true cash-generating capacity.
Investors should instead focus on AFFO, which adjusts for recurring capital expenditures and leasing costs that are essential to maintaining the portfolio. Using P/E in this context leads to a distorted view of valuation, as it ignores the capital-intensive nature of medical office facilities and the structural differences between REITs and standard industrial companies.